Choice ✔ investment

Choose stocks

Create and
share portfolios

Study reporting
public companies

ABBV - Company Financial Ratios

AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behet`s diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrm`s macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV ge

United States    http://www.abbvie.com
 sp500   
Healthcare Drug ManufacturersGeneral NYSE | New York Stock Exchange

0.953 133.17

period
2021 108.80 193 011.21 2 912.01 0.00 0.00 10.86 5.450 5.29 9.17 3.83 9.41 - 126.79
2019 81.78 121 116.00 12 772.04 15.37 0.04 - 14.82 5.260 4.30 - 11.90 3.64 8.84 - 96.45
2018 79.06 121 831.00 12 788.91 21.42 0.06 - 14.42 4.580 3.62 - 8.03 3.72 9.58 - 67.33
2017 115.88 184 944.00 9 430.96 34.84 0.10 36.29 2.220 2.57 12.89 6.55 7.50 104.16
2016 60.43 98 017.00 6 561.98 16.47 0.05 21.14 3.790 2.29 13.26 3.82 9.01 128.41
2015 54.90 89 212.00 7 002.95 17.34 0.05 22.61 3.690 2.03 12.45 3.90 9.70 130.39